Prakreeti Bhandari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prakreeti Bhandari has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Neha Mahindrakar
Department of Pediatrics Texas Tech University Health Sciences Center Lubbock Texas USA
4 shared publications - Weerapong Lilitwat
Division of Pediatric Critical Care Medicine, Department of Pediatrics, Texas Tech University Health Sciences Center School of Medicine, Lubbock, USA
4 shared publications - Yuttiwat Vorakunthada
Mass General Brigham
4 shared publications - Ramya Yedatore
Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX
2 shared publications - Maryam Zubair
Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, USA
1 shared publication Morgan Mulrooney
University Medical Center
1 shared publication
Latest Publications
- 9 November 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Tracheostomy and Home Invasive Ventilation in Severe Bronchopulmonary Dysplasia: A Scoping Review of Indications, Timing, Outcomes and Transitional Care
Aim: To map the literature on tracheostomy and home invasive ventilation in infants and children with severe bronchopulmonary dysplasia (BPD), including indications, timing, respiratory outcomes, comorbidities, complications, growth, neurodevelopment, social determinants and transitional care. Methods: We searched PubMed/MEDLINE, Embase, Scopus, Web of Science and CINAHL/EBSCO from inception to 30 June 2026. Search terms combined BPD or chronic lung disease of prematurity with tracheostomy or tracheotomy. Eligible studies included infants or children with BPD who underwent tracheostomy, received chronic invasive ventilation or were discharged on home mechanical ventilation. Conference abstracts without full‐text articles, duplicate precursor abstracts, reviews and editorials were excluded from primary synthesis. Results: Forty‐one studies were included. Evidence was mainly retrospective, including cohorts, administrative database studies, multicentre registries and single‐centre observational studies. Tracheostomy was generally considered for persistent invasive ventilation, failed extubation, high respiratory support needs, pulmonary hypertension, airway malacia, growth failure, sedation burden or limited developmental progress. Timing varied widely across centres. Pulmonary hypertension was associated with illness severity and mortality risk, although many children receiving home ventilation improved over time. Among survivors, ventilator liberation and decannulation were common but often occurred over several years. Airway complications, readmissions and operative airway interventions were frequent. Evidence also highlighted centre‐level variation, racial and social disparities and limited caregiver‐centred data. Conclusions: Tracheostomy and home invasive ventilation in severe BPD represent a prolonged care trajectory. Future work should define consensus indications, optimise timing, standardise transitional care and prioritise family‐centred and equity‐focused outcomes.
- 9 November 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Tracheostomy and Home Invasive Ventilation in Severe Bronchopulmonary Dysplasia: A Scoping Review of Indications, Timing, Outcomes and Transitional Care
Aim: To map the literature on tracheostomy and home invasive ventilation in infants and children with severe bronchopulmonary dysplasia (BPD), including indications, timing, respiratory outcomes, comorbidities, complications, growth, neurodevelopment, social determinants and transitional care. Methods: We searched PubMed/MEDLINE, Embase, Scopus, Web of Science and CINAHL/EBSCO from inception to 30 June 2026. Search terms combined BPD or chronic lung disease of prematurity with tracheostomy or tracheotomy. Eligible studies included infants or children with BPD who underwent tracheostomy, received chronic invasive ventilation or were discharged on home mechanical ventilation. Conference abstracts without full‐text articles, duplicate precursor abstracts, reviews and editorials were excluded from primary synthesis. Results: Forty‐one studies were included. Evidence was mainly retrospective, including cohorts, administrative database studies, multicentre registries and single‐centre observational studies. Tracheostomy was generally considered for persistent invasive ventilation, failed extubation, high respiratory support needs, pulmonary hypertension, airway malacia, growth failure, sedation burden or limited developmental progress. Timing varied widely across centres. Pulmonary hypertension was associated with illness severity and mortality risk, although many children receiving home ventilation improved over time. Among survivors, ventilator liberation and decannulation were common but often occurred over several years. Airway complications, readmissions and operative airway interventions were frequent. Evidence also highlighted centre‐level variation, racial and social disparities and limited caregiver‐centred data. Conclusions: Tracheostomy and home invasive ventilation in severe BPD represent a prolonged care trajectory. Future work should define consensus indications, optimise timing, standardise transitional care and prioritise family‐centred and equity‐focused outcomes.
- Open Access
- 3 November 2026
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 62
High-flow oxygen therapy delivered through tracheostomy: A scoping review of physiology, clinical applications, safety, and pediatric evidence gaps
Introduction: High-flow oxygen therapy delivered through tracheostomy (HFTO) is used for oxygenation, heated humidification, secretion management, ventilator weaning, and decannulation. Its effects depend on flow, tracheostomy interface, cuff status, and the expiratory pathway, while pediatric evidence is poorly defined. Methods: We conducted a PRISMA-ScR-guided scoping review of adult and pediatric HFTO evidence. MEDLINE/PubMed, Embase, Scopus, Web of Science, and CINAHL were searched from inception through June 30, 2026 without age or database-level language restrictions. Adult evidence was included as a comparator to define pediatric evidence gaps. Results: Of 487 records identified, 319 remained after deduplication; 134 underwent full-text/full-record assessment, 99 were excluded, and 35 sources were included (32 completed and 3 ongoing trial/protocol records). Adult flows were commonly 40-60 L/min, with experimental settings of 10-80 L/min; the pediatric simulation used 5-30 L/min. Several adult studies reported improved oxygenation, whereas others found no change; effects on work of breathing, carbon dioxide clearance, airway pressure, and lung volume were variable. Safety reporting was inconsistent. Direct pediatric evidence was limited to one infant/toddler aerosol-delivery simulation. Discussion: HFTO is an interface-dependent respiratory therapy rather than a tracheostomy equivalent of nasal high-flow therapy. Cuff status, speaking-valve configuration, expiratory patency, flow, humidification, and treatment purpose should be reported explicitly. Adult feasibility cannot be assumed to establish pediatric effectiveness or safety. Conclusion: HFTO is feasible but incompletely defined. Standardized reporting of flow, interface/cuff configuration, humidification, monitoring, adverse events, secretion outcomes, and pediatric-specific clinical outcomes is needed.
- 3 November 2026
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 62
Open AccessHigh-flow oxygen therapy delivered through tracheostomy: A scoping review of physiology, clinical applications, safety, and pediatric evidence gaps
Introduction: High-flow oxygen therapy delivered through tracheostomy (HFTO) is used for oxygenation, heated humidification, secretion management, ventilator weaning, and decannulation. Its effects depend on flow, tracheostomy interface, cuff status, and the expiratory pathway, while pediatric evidence is poorly defined. Methods: We conducted a PRISMA-ScR-guided scoping review of adult and pediatric HFTO evidence. MEDLINE/PubMed, Embase, Scopus, Web of Science, and CINAHL were searched from inception through June 30, 2026 without age or database-level language restrictions. Adult evidence was included as a comparator to define pediatric evidence gaps. Results: Of 487 records identified, 319 remained after deduplication; 134 underwent full-text/full-record assessment, 99 were excluded, and 35 sources were included (32 completed and 3 ongoing trial/protocol records). Adult flows were commonly 40-60 L/min, with experimental settings of 10-80 L/min; the pediatric simulation used 5-30 L/min. Several adult studies reported improved oxygenation, whereas others found no change; effects on work of breathing, carbon dioxide clearance, airway pressure, and lung volume were variable. Safety reporting was inconsistent. Direct pediatric evidence was limited to one infant/toddler aerosol-delivery simulation. Discussion: HFTO is an interface-dependent respiratory therapy rather than a tracheostomy equivalent of nasal high-flow therapy. Cuff status, speaking-valve configuration, expiratory patency, flow, humidification, and treatment purpose should be reported explicitly. Adult feasibility cannot be assumed to establish pediatric effectiveness or safety. Conclusion: HFTO is feasible but incompletely defined. Standardized reporting of flow, interface/cuff configuration, humidification, monitoring, adverse events, secretion outcomes, and pediatric-specific clinical outcomes is needed.
- 27 October 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 34 (1)
Endobronchial Valves for Persistent Air Leak and Bronchopleural Fistula in Children
Background: Persistent air leak (PAL) and bronchopleural fistula (BPF) are uncommon but important complications in children, particularly with necrotizing pneumonia, postoperative injury, malignancy, or extracorporeal membrane oxygenation (ECMO). When conservative therapy fails or surgery is high-risk, endobronchial or intrabronchial valve placement has emerged as a minimally invasive bronchoscopic option. This systematic review summarizes the published pediatric experience, focusing on indications, procedural approach, and outcomes. Methods: PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched from inception to June 2026, with Google Scholar and reference lists screened; no language limits applied. Eligible studies reported pediatric or late-adolescent patients who underwent bronchoscopic valve placement for PAL, BPF, or pneumothorax with ongoing air leak. Case reports, case series, and observational studies with extractable pediatric data were included. Two reviewers independently screened, assessed eligibility, and abstracted data; findings were synthesized narratively. Results: Thirteen reports were included. Valve placement achieved rapid or eventual air-leak improvement in selected children, including those with necrotizing pneumonia, postoperative air leak, chronic ventilator dependence, malignancy, and ECMO support. Reported complications included valve migration or loosening, granulation tissue, minor hemoptysis, atelectasis, contralateral pneumothorax, and recurrent air leak, although many children underwent valve removal without complication. Conclusion: Endobronchial or intrabronchial valve placement may be a useful rescue or bridge therapy for carefully selected children with refractory PAL or BPF. Evidence remains low certainty owing to small samples, retrospective design, inconsistent outcome definitions, and possible publication bias. Prospective multicenter registries with standardized reporting are needed to define optimal selection, timing, and safety.
- 27 October 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 34 (1)
Endobronchial Valves for Persistent Air Leak and Bronchopleural Fistula in Children
Background: Persistent air leak (PAL) and bronchopleural fistula (BPF) are uncommon but important complications in children, particularly with necrotizing pneumonia, postoperative injury, malignancy, or extracorporeal membrane oxygenation (ECMO). When conservative therapy fails or surgery is high-risk, endobronchial or intrabronchial valve placement has emerged as a minimally invasive bronchoscopic option. This systematic review summarizes the published pediatric experience, focusing on indications, procedural approach, and outcomes. Methods: PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched from inception to June 2026, with Google Scholar and reference lists screened; no language limits applied. Eligible studies reported pediatric or late-adolescent patients who underwent bronchoscopic valve placement for PAL, BPF, or pneumothorax with ongoing air leak. Case reports, case series, and observational studies with extractable pediatric data were included. Two reviewers independently screened, assessed eligibility, and abstracted data; findings were synthesized narratively. Results: Thirteen reports were included. Valve placement achieved rapid or eventual air-leak improvement in selected children, including those with necrotizing pneumonia, postoperative air leak, chronic ventilator dependence, malignancy, and ECMO support. Reported complications included valve migration or loosening, granulation tissue, minor hemoptysis, atelectasis, contralateral pneumothorax, and recurrent air leak, although many children underwent valve removal without complication. Conclusion: Endobronchial or intrabronchial valve placement may be a useful rescue or bridge therapy for carefully selected children with refractory PAL or BPF. Evidence remains low certainty owing to small samples, retrospective design, inconsistent outcome definitions, and possible publication bias. Prospective multicenter registries with standardized reporting are needed to define optimal selection, timing, and safety.
- 16 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (6) , 1118-1127
Hantavirus cardiopulmonary syndrome in children: a systematic scoping review of presentation, critical care management, and outcomes
Hantavirus cardiopulmonary syndrome, also termed hantavirus pulmonary syndrome (HCPS/HPS), is an uncommon zoonotic infection that may cause abrupt cardiopulmonary collapse. In the Americas, HCPS/HP...
- 16 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (6) , 1118-1127
Hantavirus cardiopulmonary syndrome in children: a systematic scoping review of presentation, critical care management, and outcomes
Hantavirus cardiopulmonary syndrome, also termed hantavirus pulmonary syndrome (HCPS/HPS), is an uncommon zoonotic infection that may cause abrupt cardiopulmonary collapse. In the Americas, HCPS/HP...